Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Lang

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|December 14, 2004
Levodopa and the progression of Parkinson's diseaseStanley Fahn, David Oakes, Ira Shoulson, et al.
Movement Disorders Clinical Practice|December 19, 2025
Diagnostic Utility of Dorsolateral Nigral Hyperintensity with Susceptibility Map-Weighted Imaging in Degenerative Parkinsonism Compared to Other Movement DisordersNathaniel Bendahan, Laura Armengou-Garcia, Mia Mojica, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 13, 2015
Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)Marios Pillas, Caroline Selai, Niall P Quinn, et al.
The New England Journal of Medicine|September 25, 2009
A double-blind, delayed-start trial of rasagiline in Parkinson's diseaseC Warren Olanow, Olivier Rascol, Robert Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Annals of Neurology|July 12, 2002
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialIra Shoulson, David Oakes, Stanley Fahn, et al.
Annals of Neurology|September 5, 2017
Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigationAnne Weissbach, Elisa Werner, Julien F Bally, et al.
Parkinsonism & Related Disorders|January 9, 2022
Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystoniaAnne Weissbach, Annika Steinmeier, Martje Pauly, et al.
Parkinsonism & Related Disorders|August 21, 2019
Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's diseaseAnne Weissbach, Kaviraja Udupa, Zhen Ni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 10, 2015
Minimal change multiple system atrophy: an aggressive variant?Helen Ling, Yasmine T Asi, Igor N Petrovic, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|December 14, 2004
Levodopa and the progression of Parkinson's diseaseStanley Fahn, David Oakes, Ira Shoulson, et al.
Movement Disorders Clinical Practice|December 19, 2025
Diagnostic Utility of Dorsolateral Nigral Hyperintensity with Susceptibility Map-Weighted Imaging in Degenerative Parkinsonism Compared to Other Movement DisordersNathaniel Bendahan, Laura Armengou-Garcia, Mia Mojica, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 13, 2015
Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)Marios Pillas, Caroline Selai, Niall P Quinn, et al.
The New England Journal of Medicine|September 25, 2009
A double-blind, delayed-start trial of rasagiline in Parkinson's diseaseC Warren Olanow, Olivier Rascol, Robert Hauser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Annals of Neurology|July 12, 2002
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialIra Shoulson, David Oakes, Stanley Fahn, et al.
Annals of Neurology|September 5, 2017
Alcohol improves cerebellar learning deficit in myoclonus-dystonia: A clinical and electrophysiological investigationAnne Weissbach, Elisa Werner, Julien F Bally, et al.
Parkinsonism & Related Disorders|January 9, 2022
Longitudinal evaluations of somatosensory-motor inhibition in Dopa-responsive dystoniaAnne Weissbach, Annika Steinmeier, Martje Pauly, et al.
Parkinsonism & Related Disorders|August 21, 2019
Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's diseaseAnne Weissbach, Kaviraja Udupa, Zhen Ni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 10, 2015
Minimal change multiple system atrophy: an aggressive variant?Helen Ling, Yasmine T Asi, Igor N Petrovic, et al.
Pageof 8